A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II

Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 05 Sep 2017 Planned initiation date changed from 6 Oct 2017 to 18 Oct 2017.
    • 17 Aug 2017 Planned End Date changed from 19 Mar 2019 to 19 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top